Contents Vol. 73, 1999
Richard Andrews, Masaaki Yamamoto, Jafri Malin Abdullah(Universiti Sains Malaysia), Dan Y. Song, Aaron Cohen‐Gadol(University of Southern California), A. Galvagni, Douglas Kondziolka(Neurological Surgery), Robert Mah, Peter J. Biggs(Massachusetts General Hospital), Michael Schulder(Northwell Health), Richard Essner(Saint John's Health Center), Dana MacPherson, John C. Flíckinger(University of Pittsburgh Medical Center), Rees Cosgrove, Andrew Kalnin, Gudrun Lange(University of York), José A. Vega, Jean‐Philippe Loeffler(Inserm), Steven L. Giannotta(Neurological Surgery), L. Dade Lunsford, Steven O’Day(Saint John's Health Center), Andrei I. Holodny(Cornell University), Allison Gray, Joseph C.T. Chen, Dimitris Stassinopoulos, Cheng Yu, Peter W. Carmel, Michel Lévesque, R. Papsin, Ajay Jawahar, Donald L. Morton(University of California, Los Angeles), Mohd Nizam Isa, Michael L.J. Apuzzo(Cornell University), J. Beatty, Charles A. Reed(Thomas Jefferson University Hospital), A. Aghevli, Venkat Narra, Fabrice Parker, Wen-Ching Liu, M. Guerrero, Jeffery A. Williams, Todd P. Thompson, Nicholas T. Zervas, Ira J. Spiro, A. Jacobs, KILVIA PINHEIRO DE FREITAS, Zbigniew Petrovich
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Experimental Observation of a Heavy Particle<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"><mml:mi>J</mml:mi></mml:math>
|Physical Review Letters|1974|1.6k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594